» Articles » PMID: 35979600

Design, Synthesis, and Biological Screening of a Series of 4'-fluoro-benzotriazole-acrylonitrile Derivatives As Microtubule-destabilising Agents (MDAs)

Overview
Specialty Biochemistry
Date 2022 Aug 18
PMID 35979600
Authors
Affiliations
Soon will be listed here.
Abstract

Colchicine-binding site inhibitors are some of the most interesting ligands belonging to the wider family of microtubule-destabilising agents. A novel series of 4'-fluoro-substituted ligands () was synthesised. The antiproliferative activity assays resulted in nM values for the new benzotriazole-acrylonitrile derivatives. Compound , the hit compound, showed an evident blockade of HeLa cell cycle in the G2-M phase, but also a pro-apoptotic potential, and an increase of early and late apoptotic cells in HeLa and MCF-7 cell cycle analysis. Confocal microscopy analysis showed a segmented shape and a collapse of the cytoskeleton, as well as a consistent cell shrinkage after administration of at 100 nM. Derivative was also proved to compete with colchicine at colchicine-binding site, lowering its activity against tubulin polymerisation. In addition, co-administration of and doxorubicin in drug-resistant A375 melanoma cell line highlighted a synergic potential in terms of inhibition of cell viability. The 4'-fluoro substitution of benzotriazole-acrylonitrile scaffold brought us a step forward in the optimisation process to obtain compound as promising MDA antiproliferative agent at nanomolar concentration.

Citing Articles

Identification of 3-Aryl-1-benzotriazole-1-yl-acrylonitrile as a Microtubule-Targeting Agent (MTA) in Solid Tumors.

Zoroddu S, Sanna L, Bordoni V, Weidong L, Gadau S, Carta A Int J Mol Sci. 2024; 25(11).

PMID: 38891892 PMC: 11172098. DOI: 10.3390/ijms25115704.


Design, Synthesis, and Antiviral Activities of New Benzotriazole-Based Derivatives.

Ibba R, Corona P, Nonne F, Caria P, Serreli G, Palmas V Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986528 PMC: 10054465. DOI: 10.3390/ph16030429.


Computational Approaches to the Rational Design of Tubulin-Targeting Agents.

Perez-Pena H, Abel A, Shevelev M, Prota A, Pieraccini S, Horvath D Biomolecules. 2023; 13(2).

PMID: 36830654 PMC: 9952983. DOI: 10.3390/biom13020285.

References
1.
Florian S, Mitchison T . Anti-Microtubule Drugs. Methods Mol Biol. 2016; 1413:403-21. DOI: 10.1007/978-1-4939-3542-0_25. View

2.
Barpe D, Dornelles Rosa D, Froehlich P . Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci. 2010; 41(3-4):458-63. DOI: 10.1016/j.ejps.2010.07.015. View

3.
Ter Haar N, Frenkel J . Treatment of hereditary autoinflammatory diseases. Curr Opin Rheumatol. 2014; 26(3):252-8. DOI: 10.1097/BOR.0000000000000059. View

4.
Lu Y, Chen J, Xiao M, Li W, Miller D . An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012; 29(11):2943-71. PMC: 3667160. DOI: 10.1007/s11095-012-0828-z. View

5.
Field J, Kanakkanthara A, Miller J . Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorg Med Chem. 2014; 22(18):5050-9. DOI: 10.1016/j.bmc.2014.02.035. View